Validation of a score based on simple hematological parameters as a predictor of mortality in hospitalized patients due to COVID-19

• Autores: Azañero-Haro, Johan, Soto, Alonso
• Formato: artículo
• Fecha de Publicación: 2025
• Institución: Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Repositorio: Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Lenguaje: español
• OAI Identifier: oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/2469
• Enlace del recurso: https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2469
• Nivel de acceso: acceso abierto
• Materia: COVID-19; SARS-CoV-2; Reglas de decisión clínica; Mortalidad; Recuento de células sanguíneas; Clinical decision rules; Mortality; Blood cell count

Introduction: During the COVID-19 pandemic, clinical prediction rules such as the PAWNN score have been developed to estimate mortality risk using only a complete blood count. However, it has not yet been validated in the Peruvian and Latin American population. Material and methods: A validation study was conducted in a retrospective cohort of patients hospitalized with COVID-19 between March and December 2020. Sensitivity, specificity, predictive values, likelihood ratios, and the area under the receiver operating characteristic curve (AUROC) for the PAWNN score were calculated. Results: A total of 1,963 patients were included, with a median age of 58 years; 66.4% were male. The mortality rate was 46.9%. Using a cutoff of 6, sensitivity was 96%, specificity was 16%, and AUROC was 0.71 (95% CI: 0.69–0.73). Conclusion: The PAWNN score does not have adequate diagnostic performance to predict mortality in patients hospitalized due to COVID-19.